Clinical trial
Effect of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, Length of Stay, and Time to Clinical Stability in Patients With Pneumonia, Sepsis, and Hypercoagulability
NCT07892794 is registered in ClinicalTrials.gov with Universitas Sebelas Maret as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, Length of Stay, and Time to Clinical Stability in Patients With Pneumonia, Sepsis, and Hypercoagulability
- Lead sponsor
- Universitas Sebelas Maret
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 14, 2025
- Completion date
- September 30, 2025
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Standard Therapy + Placebo
Participants in the placebo comparator group received standard medical treatment for pneumonia complicated by sepsis and hypercoagulability, including appropriate antimicrobial and supportive therapies, together with matching oral placebo tablets. The placebo was administered as one tablet twice daily during hospitalization until clinical stability was achieved according to Halm's Criteria.
-
Standard Therapy + Lumbrokinase DLBS1033
Participants in the experimental group received standard medical treatment for pneumonia complicated by sepsis and hypercoagulability, including appropriate antimicrobial and supportive therapies, together with oral Lumbrokinase DLBS1033 (Disolf® 490 mg). The study drug was administered as one tablet twice daily (total daily dose: 980 mg) during hospitalization until clinical stability was achieved according to Halm's Criteria.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Change From Baseline in D-Dimer Level
Changes in blood D-dimer concentration were evaluated to assess coagulation-related responses to Lumbrokinase DLBS1033. D-dimer levels were measured in ng/mL at baseline (H0), day 10 (H10), and the clinical stability-related assessment (H+1). Changes from baseline were calculated for each participant as the D-dimer concentration at H10 or H+1 minus the baseline concentration at H0. Negative values indicate a reduction in D-dimer levels. The magnitude of change was compared between the Lumbrokinase DLBS1033 and placebo groups.
-
Change From Baseline in Interleukin-6 (IL-6) Level
Changes in blood interleukin-6 (IL-6) concentration were evaluated to assess the inflammatory response to Lumbrokinase DLBS1033. IL-6 levels were measured in pg/mL at baseline (H0), day 10 (H10), and the clinical stability-related assessment (H+1). Changes from baseline were calculated for each participant as the IL-6 concentration at H10 or H+1 minus the baseline concentration at H0. Negative values indicate a reduction in IL-6 levels. The magnitude of change was compared between the Lumbrokinase DLBS1033 and placebo groups.
Lead sponsor's other trials
Universitas Sebelas Maret, most recent start first.
+24 more trials
Similar trials
Same condition (Thrombophilia) and phase, most recent start first.